Literature DB >> 10740171

Dexamethasone pharmacokinetics in the inner ear: comparison of route of administration and use of facilitating agents.

S S Chandrasekhar1, R Y Rubinstein, J A Kwartler, M Gatz, P E Connelly, E Huang, S Baredes.   

Abstract

There is growing otologic interest in treating inner ear disorders, such as sudden sensorineural hearing loss and acute or unremitting Meniere's disease, with intratympanic dexamethasone (IT-DEX). Although anecdotally reported, there are no scientific clinical papers and few prior laboratory research publications on the subject. This study compares perilymph dexamethasone concentrations after systemic and intratympanic administration and assesses the role of 3 potential transport facilitators of IT-DEX into perilymph. Forty guinea pigs (79 ears) were randomly separated into 5 groups. Dexamethasone levels were measured by radioimmunoassay. IT-DEX resulted in higher perilymph steroid levels than intravenous dexamethasone (P < 0.05). Histamine facilitator resulted in significantly higher perilymph steroid levels than IT-DEX alone (P < 0.05). Neither hyaluronic acid nor dimethylsulfoxide was a potent facilitator. This study demonstrates that IT-DEX administration results in superior perilymph levels within 1 hour of administration and does not result in systemic absorption. Histamine is a potent facilitating agent. The clinical implications are considerable.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10740171     DOI: 10.1067/mhn.2000.102578

Source DB:  PubMed          Journal:  Otolaryngol Head Neck Surg        ISSN: 0194-5998            Impact factor:   3.497


  57 in total

1.  Hyaluronic acid enhances gene delivery into the cochlea.

Authors:  Seiji B Shibata; Sarah R Cortez; James A Wiler; Donald L Swiderski; Yehoash Raphael
Journal:  Hum Gene Ther       Date:  2012-02-08       Impact factor: 5.695

2.  Intratympanic steroids in severe to profound sudden sensorineural hearing loss as salvage treatment.

Authors:  Jong Dae Lee; Moo Kyun Park; Chi-Kyou Lee; Kye Hoon Park; Byung Don Lee
Journal:  Clin Exp Otorhinolaryngol       Date:  2010-09-17       Impact factor: 3.372

3.  Therapy of hearing disorders - conservative procedures.

Authors:  Stefan Plontke
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2005-09-28

4.  Intratympanic dexamethasone perfusion versus injection for treatment of refractory sudden sensorineural hearing loss.

Authors:  Lihua Li; Jihao Ren; Tuanfang Yin; Wei Liu
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-06-06       Impact factor: 2.503

5.  [Intratympanic injection therapy for therapy refractory acute hearing loss: A safe option for secondary treatment].

Authors:  G Mühlmeier; S Maier; M Maier; H Maier
Journal:  HNO       Date:  2015-10       Impact factor: 1.284

Review 6.  Local inner-ear drug delivery and pharmacokinetics.

Authors:  Alec N Salt; Stefan K R Plontke
Journal:  Drug Discov Today       Date:  2005-10-01       Impact factor: 7.851

Review 7.  Intratympanic steroid therapy for inner ear diseases, a review of the literature.

Authors:  M J R C Alles; M A der Gaag; R J Stokroos
Journal:  Eur Arch Otorhinolaryngol       Date:  2006-05-25       Impact factor: 2.503

Review 8.  Animal model studies yield translational solutions for cochlear drug delivery.

Authors:  R D Frisina; M Budzevich; X Zhu; G V Martinez; J P Walton; D A Borkholder
Journal:  Hear Res       Date:  2018-05-05       Impact factor: 3.208

9.  Intratympanic dexamethasone with hyaluronic acid in the treatment of idiopathic sudden sensorineural hearing loss after failure of intravenous steroid and vasoactive therapy.

Authors:  Haralampos Gouveris; Oksana Selivanova; Wolf Mann
Journal:  Eur Arch Otorhinolaryngol       Date:  2004-04-29       Impact factor: 2.503

Review 10.  Is gentamycin delivery via sustained-release vehicles a safe and effective treatment for refractory Meniere's disease? A critical analysis of published interventional studies.

Authors:  Petros V Vlastarakos; Emily Iacovou; Thomas P Nikolopoulos
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-09-13       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.